Dublin, Jan. 29, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/lhn224/drug_discovery) has announced the addition of the "Drug Discovery Outsourcing Global Market - Forecast To 2022" report to their offering.
Over the last two decades, the Pharmaceutical/Biotech industry has undergone radical changes. The unprecedented downsizing of the internal discovery of big pharmaceuticals, patent expiration, shift towards biologics have seen a surge in the externalization and outsourcing activities.
As the industry is looking for new sources of discovery and innovation with limited resources, there is a growing preference to move towards externalization and willingness to embrace the concept of outsourcing.
Almost all the major Pharmaceutical/biotech companies are considering outsourcing as a core strategy to fill their discovery pipelines. Outsourcing companies that have precise capabilities through greater flexibility are the preferred ones. Now-a-days, the big pharma relies more on CRO's for drug discovery capabilities to stock up their pipelines.
This report provides comprehensive insights on the global drug discovery outsourcing market. The report covers all segments, global trends and emerging strategies of the outsourcing market related to drug discovery. Major Drug Discovery Outsourcing (DDO) players included in the report are Evotec, Charles River Laboratories (CRL), Pharmaceutical Product Development (PPD), WuxiApptec, ChemPartner, Syngene, Aurigene, Jubilant Biosys, Advinus, GVK Biosciences, TCG Lifesciences and AMRI.
This report caters to the need of Contract research organizations, Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Service providers and other associated stake holders to identify and analyze the potential of the DDO market. The report also provides insights on customer base, number of deals between CRO's and Pharmaceutical /biotech firms, global FTE rates, employee strength & number of companies, revenue per employee of major players, therapeutic area gap analysis and successful research collaboration outcomes of selected CRO's and Sponsors, which are likely to have an impact on the DDO market in the foreseeable future.
This report covers in-depth analysis of major players by therapeutic area of focus, capabilities, geographic presence, business models, financials, collaborations, acquisitions, various marketing strategies adopted along with insightful analysis on conferences, clusters and match making websites.
Key Topics Covered:
1 Introduction
2 Market Analysis
2.1 Research Methodology
2.2 Forecasting Model
2.3 Market Dynamics
2.4 Market Sizing
2.5 Emerging Trends & Strategies
3 Business Overview
3.1 Business Models
3.2 Business Evolution
3.3 Certifications
3.4 Dd Indicators
3.5 Pharma R&D Exp & Intensity
4 Competitor Analysis
4.1 Therapeutic Area Matrix
4.2 Global Fte Rates
4.3 Regional Revenues Vs Fte
4.4 Keyplayers (Revenue Per Employee, Customers, Deals & Ta Pie Chart, Collaboration Outcomes)
5 Leading Players
5.1 Overview
5.2 Capabilities
5.3 Therapeutic Area
5.4 Business Models
5.5 Collaborations
5.6 Acquisitions
6 Marketing Strategies
6.1 Conferences
6.1.1 Conferences -2014, 2015, 2016
6.1.2 Conference Analysis- 2014-15
6.2 Match Making Websites
6.3 Virtual Pharmaceuticals
6.4 Online Rpfs
6.5 Networking Websites
6.6 Clusters
6.7 Other Marketing Strategies
6.7.1 Website Rankings, Linkedin Followers, Google Search Volumes
Companies Mentioned
- Advinus
- AMRI Global
- Aurigene
- Charles River Laboratories
- Chempartner
- Evotec
- Gvk Biosciences
- Jubilant Biosys
- Pharmaceutical Product Development
- Syngene
- TCG Lifesciences
- Wuxiapptec
For more information visit http://www.researchandmarkets.com/research/lhn224/drug_discovery
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Drug Discovery, Consulting and Outsourcing


Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 



